Publikationen von Tibor Stark

Frescura, F.; Stark, T.; Tiziani, E.; Di Martino, S.; Ruda-Kucerova, J.; Drago, F.; Ferraro, L.; Micale, V.; Beggiato, S.: Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats. PHARMACOLOGICAL REPORTS (2024)

Di Bartolomeo, M.; Stark, T.; Di Martino, S.; Iannotti, F. A.; Ruda-Kucerova, J.; Romano, G. L.; Kuchar, M.; Laudani, S.; Palivec, P.; Piscitelli, F. et al.; Wotjak, C. T.; Bucolo, C.; Drago, F.; Di Marzo, V.; D'Addario, C.; Micale, V.: The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 (4), 3907 (2023)

van Doeselaar, L.; Stark, T.; Mitra, S.; Yang, H.; Bordes, J.; Stolwijk, L.; Engelhardt, C.; Kovarova, V.; Narayan, S.; Brix, L. M. et al.; Springer, M.; Deussing, J. M.; Lopez, J. P.; Czisch, M.; Schmidt, M. V.: Sex-specific and opposed effects of FKBP51 in glutamatergic and GABAergic neurons: Implications for stress susceptibility and resilience. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 120 (23), e2300722120 (2023)

Stark, T.; Iannotti, F. A.; Di Martino, S.; Di Bartolomeo, M.; Ruda-Kucerova, J.; Piscitelli, F.; Wotjak, C. T.; D'Addario, C.; Drago, F.; Di Marzo, V. et al.; Micale, V.: Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. BIOMOLECULES 12 (1), 108 (2022)

Di Bartolomeo, M.; Stark, T.; Maurel, O. M.; Iannotti, F. A.; Kuchar, M.; Ruda-Kucerova, J.; Piscitelli, F.; Laudani, S.; Pekarik, V.; Salomone, S. et al.; Arosio, B.; Mechoulam, R.; Maccarrone, M.; Drago, F.; Wotjak, C. T.; Di Marzo, V.; Vismara, M.; Dell'Osso, B.; D'Addario, C.; Micale, V.: Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Delta 9-tetrahydrocannabinol-exposed rats. PHARMACOLOGICAL RESEARCH 164, 105357 (2021)

Ebert, T.; Heinz, D. E.; Almeida-Correa, S.; Cruz, R.; Dethloff, F.; Stark, T.; Bajaj, T.; Maurel, O. M.; Ribeiro, F. M.; Calcagnini, S. et al.; Hafner, K.; Gassen, N. C.; Turck, C. W.; Boulat, B.; Czisch, M.; Wotjak, C. T.: Myo-Inositol Levels in the Dorsal Hippocampus Serve as Glial Prognostic Marker of Mild Cognitive Impairment in Mice. FRONTIERS IN AGING NEUROSCIENCE 13, 731603 (2021)

Ruat, J.; Heinz, D. E.; Binder, F. P.; Stark, T.; Neuner, R.; Hartmann, A.; Kaplick, P. M.; Chen, A.; Czisch, M.; Wotjak, C. T.: Structural correlates of trauma-induced hyperarousal in mice. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 111, 110404 (2021)

Di Bartolomeo, M.; Stark, T.; Iannotti, F. A.; Maccarrone, M.; Drago, F.; Dell'Osso, B.; Micale, V.; D'Addario, C.: Cannabinoid CB1 and dopamine D2 receptors transcriptional dysregulation in perinatal delta-9-tetrahydrocannabinol exposed rats and in schizophrenic subjects. EUROPEAN NEUROPSYCHOPHARMACOLOGY 40, S. S300 - S301 (2020)

Horska, K.; Kotolova, H.; Karpisek, M.; Babinska, Z.; Hammer, T.; Prochazka, J.; Stark, T.; Micale, V.; Ruda-Kucerova, J.: Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. TOXICOLOGY AND APPLIED PHARMACOLOGY 406, 115214 (2020)

Stark, T.; Iannotti, F. A.; Piscitelli, F.; Ruda-Kucerova, J.; Drago, F.; Sulcova, A.; Di Marzo, V.; Micale, V.: Neonatal CB1 receptor blockade differentially affects behavioural responses in normal and prenatally MAM exposed rats. In EUROPEAN NEUROPSYCHOPHARMACOLOGY, 29, S. S477 - S477. 32nd Congress of the European-College-of-Neuropsychopharmacology (ECNP), Copenhagen, DENMARK, 07. September 2019 - 10. September 2019. (2019)

Micale, V.; Di Bartolomeo, M.; Di Martino, S.; Stark, T.; Dell'Osso, B.; Drago, F.; D'Addario, C.: Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. PHARMACOLOGY & THERAPEUTICS 241, 108279 (2023)

Stark, T.; Di Martino, S.; Drago, F.; Wotjak, C. T.; Micale, V.: Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. PHARMACOLOGICAL RESEARCH 174, 105938 (2021)